FDA approves Dova platelet-producing receptor agonist Doptelet extended indications
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently,The FDA(http://approved Dova (dova
Pharmaceutical(http://) of the platelet receptor agonist Doptelet extended indications to treat adult patients with chronic immunoglotosis (ITP)DopteletDoptelet is the first commercial
product(http://of Dova Pharmaceuticals, approved by the FDA in May 2018 to help replace platelet infusions in patients with certain chronic liver diseases, and fda approval for the treatment of ITP in June 2019the new price can be matched by itP'sdrug(http://in the platelet receptor agonist categoryDespite this, Evercore ISIAnalytics(http://said in a memo released to clients on Thursday that The price of Doptelet is still 40 percent higher than Promacta, a similar oral drug, and 12 percent higher than the price of Ampin's weekly injectionsAnalysts expect Dova Pharmaceuticals to account for $200 million to $250 million in the $1 billion U.Smarket for ITP productsInvestors were equally bullish on Dova's performance, with its share price rising about 30 per centDoptelet has some advantages over existing drugsWith Amin's Nplate, patients must be given weekly injections by a health care provider, and Doptelet is a daily oral drugNovartis Promacta is also an oral drug, but it has a certain risk of the liver and needs to be monitored for liver function during treatment
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.